Avantium and AmBev, part of AB InBev Group, have inked an agreement on PEF for soft drink bottles.
With a Series A funding of CHF 30m from Versant Ventures, Vector Biopharma AG set out to solve several of the current gene delivery problems.
Swiss-headquarterd Novartis AG has reported two cases of fatal liver failure after treatment with the gene therapy Zolgensma.
Azenta Inc has entered into an agreement to acquire B Medical Systems S.á r.l. and its subsidiaries for €410m.
Sartorius Stedim Biotech has purchased the world’s largest human albumin producer Albumedix to broaden its product portfolio in animal-free cell media and to stabilise protein drugs.
As Genmab’s Hexabody tumour antibody platform is advancing, BioNTech has secured a licence in the field of immunotherapy to co-develop antibodies on 50:50 base.
British antifungal developer F2G Ltd has announced a $70mn financing round to push development of its late-stage compound olorofilm.
Sosei Heptares and AbbVie have inked a multi-target licence option drug discovery agreement in neurology.
Researchers have presented a novel method to promote biofilm formation and thus to increase efficiency of biocatalysis in biotech production.
InflaRx plans to apply for Emergency Use Authorization from the US FDA in Q3/2022 for vilobelimab, the company’s treatment for critically ill COVID-19 patients.